Published in Curr Treat Options Gastroenterol on March 01, 2015
Eosinophils in Gastrointestinal Disorders: Eosinophilic Gastrointestinal Diseases, Celiac Disease, Inflammatory Bowel Diseases, and Parasitic Infections. Immunol Allergy Clin North Am (2015) 0.87
Diet, gut microbes, and the pathogenesis of inflammatory bowel diseases. Mol Nutr Food Res (2016) 0.85
Pathway-based approaches to the treatment of inflammatory bowel disease. Transl Res (2015) 0.83
Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches. Gastroenterology (2016) 0.83
Potential Benefits of Dietary Fibre Intervention in Inflammatory Bowel Disease. Int J Mol Sci (2016) 0.76
The microbiota in inflammatory bowel disease: current and therapeutic insights. J Inflamm Res (2017) 0.75
The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions. Therap Adv Gastroenterol (2016) 0.75
Innate immune responses to gut microbiota differ between oceanic and freshwater threespine stickleback populations. Dis Model Mech (2015) 0.75
An obesity-associated gut microbiome with increased capacity for energy harvest. Nature (2006) 44.35
Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med (2013) 20.65
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med (2009) 16.02
Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A (2008) 14.18
Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science (2010) 12.54
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature (2012) 10.74
The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe (2014) 7.43
Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature (2013) 6.45
Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science (2000) 6.19
The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science (2011) 6.01
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol (2012) 5.66
Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature (2013) 5.47
Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology (2007) 5.40
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet (1999) 5.36
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology (2000) 5.34
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology (2003) 4.40
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut (2004) 3.80
Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology (2008) 3.79
Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology (1995) 3.44
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol (2010) 3.32
Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol (2010) 3.12
Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut (2011) 3.11
Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis (2014) 3.04
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut (2004) 3.01
Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity (2014) 2.69
Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology (1998) 2.62
Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr (2013) 2.57
Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J Clin Invest (2014) 2.39
The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol (2009) 2.35
Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol (2009) 2.34
Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut (1991) 2.24
Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology (2011) 2.21
Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr (2015) 2.10
The effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis. Aliment Pharmacol Ther (2013) 2.01
Fungi and inflammatory bowel diseases: Alterations of composition and diversity. Scand J Gastroenterol (2008) 1.89
Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm Bowel Dis (2007) 1.85
Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis (2013) 1.79
Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet (1989) 1.76
Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther (2006) 1.76
Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2005) 1.73
Analysis of bacterial bowel communities of IBD patients: what has it revealed? Inflamm Bowel Dis (2008) 1.72
Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol (2010) 1.61
Recovery of the gut microbiome following fecal microbiota transplantation. MBio (2014) 1.59
Efficacy of different therapeutic options for spontaneous abdominal abscesses in Crohn's disease: are antibiotics enough? Inflamm Bowel Dis (2011) 1.50
Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology (2002) 1.40
Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol (2015) 1.33
Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci (1999) 1.29
A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol (1999) 1.27
Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology (1982) 1.26
Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci (1994) 1.26
Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther (1999) 1.24
Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis (2002) 1.23
A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis (2001) 1.19
Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther (2003) 1.19
Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology (2008) 1.19
The role of mucosal immunity and host genetics in defining intestinal commensal bacteria. Curr Opin Gastroenterol (2010) 1.15
Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis (2009) 1.14
High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum (2007) 1.12
Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther (2005) 1.10
Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther (2002) 1.07
Study of the viral and microbial communities associated with Crohn's disease: a metagenomic approach. Clin Transl Gastroenterol (2013) 1.06
Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol (1994) 1.06
High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. J Gastroenterol Hepatol (2007) 1.04
Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis. Am J Gastroenterol (2014) 1.04
Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther (2003) 1.03
Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther (2004) 1.02
Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. Dis Colon Rectum (2007) 1.00
Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev (2011) 1.00
Dysbiosis of gut fungal microbiota is associated with mucosal inflammation in Crohn's disease. J Clin Gastroenterol (2014) 0.99
Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon Rectum (2002) 0.99
Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst Rev (2008) 0.97
The role of antibiotics and probiotics in pouchitis. Ann Gastroenterol (2012) 0.95
Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease. Aliment Pharmacol Ther (2010) 0.95
Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Aliment Pharmacol Ther (2007) 0.94
Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis. Am J Gastroenterol (2011) 0.93
Bacteriophages in gut samples from pediatric Crohn's disease patients: metagenomic analysis using 454 pyrosequencing. Inflamm Bowel Dis (2013) 0.92
A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol (2001) 0.91
Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. Dig Dis Sci (2007) 0.91
A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis (2011) 0.91
Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis (2007) 0.90
Acute and chronic pouchitis--pathogenesis, diagnosis and treatment. Nat Rev Gastroenterol Hepatol (2012) 0.90
Prebiotics in chronic intestinal inflammation. Inflamm Bowel Dis (2009) 0.88
Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. Exp Ther Med (2012) 0.88
Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease. Aliment Pharmacol Ther (2010) 0.87
Long-term alteration of intestinal microbiota in patients with ulcerative colitis by antibiotic combination therapy. PLoS One (2014) 0.85
Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum. Int J Immunopathol Pharmacol (2014) 0.84
Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation? Proc Nutr Soc (2014) 0.83
Antibiotics and inflammatory bowel diseases. Dig Dis (2013) 0.83
Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: a preliminary report. J Crohns Colitis (2014) 0.83
Addition of metronidazole to azathioprine for the prevention of postoperative recurrence of Crohn's disease: a randomized, double-blind, placebo-controlled trial. Inflamm Bowel Dis (2013) 0.81
Update on the pathogenesis and management of pouchitis. Curr Infect Dis Rep (2014) 0.81
Serial changes of cytokines in active ulcerative colitis: effects of antibiotic combination therapy. Hepatogastroenterology (2009) 0.80
Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis (2013) 0.80
Antibiotics, probiotics and prebiotics in IBD. Nestle Nutr Inst Workshop Ser (2014) 0.80
An open study of maintenance antibiotic therapy for chronic antibiotic-dependent pouchitis: efficacy, complications and outcome. Colorectal Dis (2011) 0.76
Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe (2008) 11.08
Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell (2012) 4.98
Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology (2005) 4.10
VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol (2005) 2.90
Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis (2010) 2.62
Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases. Curr Opin Infect Dis (2009) 2.44
The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications. J Gastroenterol (2014) 2.32
The hedgehog signalling pathway in the gastrointestinal tract: implications for development, homeostasis, and disease. Gastroenterology (2005) 2.12
Induction of persistent colitis by a human commensal, enterotoxigenic Bacteroides fragilis, in wild-type C57BL/6 mice. Infect Immun (2009) 2.05
Interleukin-10 blocked endoplasmic reticulum stress in intestinal epithelial cells: impact on chronic inflammation. Gastroenterology (2006) 1.93
Inflammatory bowel diseases phenotype, C. difficile and NOD2 genotype are associated with shifts in human ileum associated microbial composition. PLoS One (2012) 1.82
Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe (2012) 1.81
Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110δ. Gastroenterology (2010) 1.80
Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: summary of a symposium. Alcohol (2008) 1.76
Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm Bowel Dis (2002) 1.70
IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. Hepatology (2014) 1.69
Mouse Paneth cell antimicrobial function is independent of Nod2. Gut (2013) 1.69
An update on the use and investigation of probiotics in health and disease. Gut (2013) 1.62
STAT3 regulates NF-kappaB recruitment to the IL-12p40 promoter in dendritic cells. Blood (2004) 1.58
Vitamin D receptor negatively regulates bacterial-stimulated NF-kappaB activity in intestine. Am J Pathol (2010) 1.57
Dual-association of gnotobiotic IL-10-/- mice with 2 nonpathogenic commensal bacteria induces aggressive pancolitis. Inflamm Bowel Dis (2007) 1.55
Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol (2011) 1.49
IKK beta and phosphatidylinositol 3-kinase/Akt participate in non-pathogenic Gram-negative enteric bacteria-induced RelA phosphorylation and NF-kappa B activation in both primary and intestinal epithelial cell lines. J Biol Chem (2002) 1.48
Investigating the biological and clinical significance of human dysbioses. Trends Microbiol (2011) 1.48
Episodic retreatment versus scheduled maintenance therapy of crohn's disease with infliximab: not so far apart. Gastroenterology (2004) 1.43
Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis (2013) 1.33
Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol (2004) 1.23
Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis. Gastroenterology (2010) 1.20
Antigen-presenting cell production of IL-10 inhibits T-helper 1 and 17 cell responses and suppresses colitis in mice. Gastroenterology (2011) 1.19
Mouse background strain profoundly influences Paneth cell function and intestinal microbial composition. PLoS One (2012) 1.19
Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Gut Pathog (2010) 1.17
Interleukin 10-deficient mice exhibit defective colonic Muc2 synthesis before and after induction of colitis by commensal bacteria. Inflamm Bowel Dis (2004) 1.15
The role of mucosal immunity and host genetics in defining intestinal commensal bacteria. Curr Opin Gastroenterol (2010) 1.15
Bacterial symbionts induce a FUT2-dependent fucosylated niche on colonic epithelium via ERK and JNK signaling. Am J Physiol Gastrointest Liver Physiol (2007) 1.08
Gene expression patterns in experimental colitis in IL-10-deficient mice. Inflamm Bowel Dis (2009) 1.08
The Immunostimulatory Nature of NSAIDs in Inflammatory Bowel Disease. Inflamm Bowel Dis (2015) 1.07
Inflammatory-mediated repression of the rat ileal sodium-dependent bile acid transporter by c-fos nuclear translocation. Gastroenterology (2002) 1.06
Chronic intestinal inflammation induces stress-response genes in commensal Escherichia coli. Gastroenterology (2011) 1.02
Lipopolysaccharide activates innate immune responses in murine intestinal myofibroblasts through multiple signaling pathways. Am J Physiol Gastrointest Liver Physiol (2009) 1.01
Wnt2 inhibits enteric bacterial-induced inflammation in intestinal epithelial cells. Inflamm Bowel Dis (2011) 0.99
IL-10 regulates Il12b expression via histone deacetylation: implications for intestinal macrophage homeostasis. J Immunol (2012) 0.99
Dysregulation of immune homeostasis in autoimmune diseases. Nat Med (2012) 0.98
IL-10 gene-deficient mice lack TGF-beta/Smad-mediated TLR2 degradation and fail to inhibit proinflammatory gene expression in intestinal epithelial cells under conditions of chronic inflammation. Ann N Y Acad Sci (2006) 0.98
Altered enteric microbiota ecology in interleukin 10-deficient mice during development and progression of intestinal inflammation. Gut Microbes (2013) 0.97
Irgm1-deficient mice exhibit Paneth cell abnormalities and increased susceptibility to acute intestinal inflammation. Am J Physiol Gastrointest Liver Physiol (2013) 0.97
Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda. Inflamm Bowel Dis (2013) 0.97
Intestinal heat shock protein 110 regulates expression of CD1d on intestinal epithelial cells. J Clin Invest (2003) 0.96
Growth hormone reduces the severity of fibrosis associated with chronic intestinal inflammation. Gastroenterology (2005) 0.95
Translational research: Bridging the widening gap between basic and clinical research. Gastroenterology (2003) 0.94
Modulation of inflammation by kininogen deficiency in a rat model of inflammatory arthritis. Arthritis Rheum (2005) 0.94
The colitis-associated transcriptional profile of commensal Bacteroides thetaiotaomicron enhances adaptive immune responses to a bacterial antigen. PLoS One (2012) 0.93
CD4+CD25+ cell depletion from the normal CD4+ T cell pool prevents tolerance toward the intestinal flora and leads to chronic colitis in immunodeficient mice. Inflamm Bowel Dis (2006) 0.91
NF-kappaB-inducing kinase restores defective IkappaB kinase activity and NF-kappaB signaling in intestinal epithelial cells. Cell Signal (2004) 0.91
Bifidobacterium animalis causes extensive duodenitis and mild colonic inflammation in monoassociated interleukin-10-deficient mice. Inflamm Bowel Dis (2009) 0.90
Challenges in IBD Research: updating the scientific agendas. Inflamm Bowel Dis (2003) 0.90
Dendritic cells in germ-free and specific pathogen-free mice have similar phenotypes and in vitro antigen presenting function. Immunol Lett (2005) 0.90
Induction of bacterial antigen-specific colitis by a simplified human microbiota consortium in gnotobiotic interleukin-10-/- mice. Infect Immun (2014) 0.88
Treatment of inflammatory bowel disease with antibiotics. Gastroenterol Clin North Am (2004) 0.88
Kininogen deficiency modulates chronic intestinal inflammation in genetically susceptible rats. Am J Physiol Gastrointest Liver Physiol (2002) 0.88
Inflammation-associated adherent-invasive Escherichia coli are enriched in pathways for use of propanediol and iron and M-cell translocation. Inflamm Bowel Dis (2014) 0.87
Innate PI3K p110δ regulates Th1/Th17 development and microbiota-dependent colitis. J Immunol (2014) 0.87
A novel human fibroblast growth factor treats experimental intestinal inflammation. Gastroenterology (2002) 0.86
Thymic development of autoreactive T cells in NOD mice is regulated in an age-dependent manner. J Immunol (2013) 0.86
Dysregulated luminal bacterial antigen-specific T-cell responses and antigen-presenting cell function in HLA-B27 transgenic rats with chronic colitis. Immunology (2005) 0.85
Villous B cells of the small intestine are specialized for invariant NK T cell dependence. J Immunol (2008) 0.85
High throughput sequencing reveals distinct microbial populations within the mucosal and luminal niches in healthy individuals. Gut Microbes (2015) 0.84
Enterococcus faecalis strains differentially regulate Alix/AIP1 protein expression and ERK 1/2 activation in intestinal epithelial cells in the context of chronic experimental colitis. J Proteome Res (2009) 0.84
Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome. Dig Dis Sci (2004) 0.84
The mutation Ser511Asn leads to N-glycosylation and increases the cleavage of high molecular weight kininogen in rats genetically susceptible to inflammation. Blood (2003) 0.83
Transcriptome analysis of Enterococcus faecalis toward its adaption to surviving in the mouse intestinal tract. Arch Microbiol (2014) 0.82
CD4(+) T lymphocytes mediate colitis in HLA-B27 transgenic rats monoassociated with nonpathogenic Bacteroides vulgatus. Inflamm Bowel Dis (2007) 0.82
Endogenous antigen presenting cell-derived IL-10 inhibits T lymphocyte responses to commensal enteric bacteria. Immunol Lett (2009) 0.81
Antithrombotic activity of kininogen is mediated by inhibitory effects of domain 3 during arterial injury in vivo. Am J Physiol Heart Circ Physiol (2007) 0.79
Colonic expression of the peptide transporter PEPT1 is downregulated during intestinal inflammation and is not required for NOD2-dependent immune activation. Inflamm Bowel Dis (2014) 0.79
Inflammation-induced acid tolerance genes gadAB in luminal commensal Escherichia coli attenuate experimental colitis. Infect Immun (2013) 0.76
Response to the letter by Brotherton regarding "insoluble fiber and intestinal microbiota metabolism". J Gastroenterol (2015) 0.75
Erratum: NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growth. Nat Immunol (2017) 0.75
Discordant research opportunities and human resources: can we meet the challenge? Gastroenterology (2002) 0.75
Are we losing control? Medical costs can no longer be ignored. Gastroenterology (2005) 0.75
Our new president--Robert S. Sandler, MD, MPH. Gastroenterology (2008) 0.75
Aberrant innate immune responses in TLR-ligand activated HLA-B27 transgenic rat cells. Inflamm Bowel Dis (2008) 0.75
Pharmaceutical influence on clinical science and practice: a double-edged sword. Gastroenterology (2004) 0.75
Reduced responsiveness of HLA-B27 transgenic rat cells to TGF-beta and IL-10-mediated regulation of IFN-gamma production. Inflamm Bowel Dis (2008) 0.75
Corrigendum: NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growth. Nat Immunol (2017) 0.75